Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) in Vitiligo. The expected timing is based on the latest available company guidance and may change.
01/12/26:- Ongoing Ph2 proof-of-concept ZORYVE foam vitiligo trial; decision on program advancement in Q4 2026. 02/25/26:- Ongoing Ph2 ZORYVE foam vitiligo study; advancement decision remains expected in Q4 2026. 05/06/26:- Ph2 ZORYVE foam vitiligo trial enrollment ongoing; results and advancement decision expected in Q4 2026. 08/05/26:- Ph2 vitiligo enrollment completed; topline results and advancement decision expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.